Cannell Capital LLC Purchases Shares of 381,323 Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Cannell Capital LLC acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 381,323 shares of the company's stock, valued at approximately $5,079,000. Eton Pharmaceuticals accounts for about 1.0% of Cannell Capital LLC's holdings, making the stock its 28th largest position. Cannell Capital LLC owned approximately 1.46% of Eton Pharmaceuticals at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ETON. Jane Street Group LLC purchased a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at approximately $90,000. Raymond James Financial Inc. purchased a new stake in Eton Pharmaceuticals in the fourth quarter valued at approximately $147,000. Hillsdale Investment Management Inc. acquired a new position in Eton Pharmaceuticals during the fourth quarter worth $226,000. Envestnet Asset Management Inc. purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter worth $236,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter worth $373,000. Institutional investors and hedge funds own 27.86% of the company's stock.

Eton Pharmaceuticals Trading Up 4.0 %

ETON traded up $0.48 on Friday, hitting $12.45. 201,772 shares of the company were exchanged, compared to its average volume of 170,173. The firm has a 50-day moving average price of $14.53 and a two-hundred day moving average price of $12.47. Eton Pharmaceuticals, Inc. has a twelve month low of $3.03 and a twelve month high of $18.41. The company has a market cap of $333.88 million, a price-to-earnings ratio of -56.59 and a beta of 1.34.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). The business had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. Equities analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ETON shares. Craig Hallum increased their target price on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Finally, B. Riley reissued a "buy" rating and issued a $24.00 price objective (up previously from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.